Capecitabine and oral cyclophosphamide: A novel oral treatment combination for advanced cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 3, Issue 2, 2007, Pages 99-105

  Findlay, Michael ^a,e   Sharples, Katrina ^b   Riley, Greta A ^a   Simpson, Andrew ^a   Ackland, Stephen ^c   Hall, Katherine ^c   Isaacs, Richard ^d   Humm, Gillian ^d   Mckeage, Mark J ^e  

^a WELLINGTON HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c NEWCASTLE MATER HOSPITAL   (Australia)

^d PALMERSTON NORTH HOSPITAL   (New Zealand)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Administration; Anti neoplastic combined chemotherapy protocol; Capecitabine; Clinical trial; Cyclophosphamide; Oral; Phase I

Indexed keywords

ANTIEMETIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE;

ABDOMINAL PAIN; ACIDOSIS; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; DYSURIA; EDEMA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEMATEMESIS; HEMATURIA; HUMAN; KIDNEY DISEASE; LUNG DISEASE; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN DISEASE; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; URINARY FREQUENCY;

EID: 34249979782     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2007.00095.x     Document Type: Article

References (12)

1. Lui G Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-15.
2. Schuller J, Cassidy J, Dumont E et al. Preferential activation of capecitabine in tumour following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45: 291-7.
3. Endo M Shinbori N, Fukase Y, Sawada N, Ishikawa T, Ishitsuka H, Tanaka Y. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999; 83: 127-34.
4. Engelsman E, Klijn JC, Rubens RD et al. "Classical"CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-Operative Group Phase III Trial (10808). Eur J Cancer 1991; 27: 966-70.
5. Bertolini B, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 4341-6.
6. The Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.
7. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. J Clin Oncol 2000; 18: 1337-45.
8. Liu JJ, Kestell P, Findlay M et al. Application of liquid chromatography-mass spectrometry to monitoring plasma cyclophosphamide levels in phase I trial cancer patients. Clin Exp Pharmacol Physiol 2004; 31: 677-82.
9. Tong DK Cheng CW, Ching Chan S, Ngor Wong L, Chow LW. Phase II study of an "all-oral"regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer - safety, efficacy and quality of life. Oncology 2005; 68: 520-5.
10. Nole F, Catania C, Sanna G et al. Dose-finding and pharmacokinetic study of an all oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006; 17: 322-9.
11. Sharma R, Ong S, Li K et al. Phase II study of fixed dose capecitabine and assessment of thymidine and folate concentration as predictors of toxicity in advanced colorectal cancer patients (pts). J Clin Oncol ASCO Annual Meeting Proceedings 2003; 21: Abs. 573 [Abstract].
12. Colleoni M, Gelber S, Goldhirsh A. Treatment of advanced breast cancer: the good, the bad and the ugly. Ann Oncol 2005; 16: 1219-21.